Analyst: Slow penetration for alcohol pill
Last week’s approval of Lundbeck’s alcohol pill will not add much to company turnover this year or the next, says an analyst, who has markedly lower expectations for the drug than Lundbeck does.
by Stefan Singh Kailay
“As I see it you should not expect any significant contribution from Selincro. The contribution from this drug will be very limited in 2013,” says Sydbank analyst, Søren Løntoft Hansen, following last week’s European approval of the Selincro, a pill to treat alcohol addiction.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
